ASH 2023 | Comparing TTNT or death between front-line DRd and VRd in transplant-ineligible multiple myeloma
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, discusses a retrospective cohort study which used electronic medical record data to compare the time to next treatment (TTNT) or death in transplant-ineligible patients with multiple myeloma (MM) treated in the front-line setting with either daratumumab, lenalidomide and dexamethasone (DRd) or bortezomib, lenalidomide and dexamethasone (VRd). Treatment with DRd was found to result in longer TTNT or death, which may be useful knowledge when choosing between the two treatment regimens in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Bristol Myers Squibb, Karyopharm, Janssen, Pfizer; Membership on an entity’s Board of Directors or advisory committees: Bristol Myers Squibb, Pfizer; Research Funding: Bristol Myers Squibb, Karyopharm, International Myeloma Society Young Investigator Award, Pentecost Family Myeloma Research Center; Honoraria: OncLive, Survivorship
